Antipodean Advisors’s Precigen PGEN Stock Holding History

Antipodean Advisors’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-58,522	Closed	-$1.41M	–	20
2016 Q4	$1.41M	Buy	58,522 +15,135	+35%	+$421K	0.56%	19
2016 Q3	$1.21M	Buy	+43,387	New	+$1.15M	0.6%	16

Other funds holding PGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Antipodean Advisors's PGEN Position: Q1 2017 in Review

Antipodean Advisors sold out of Precigen (PGEN) in Q1 2017, closing a stake of 58,522 shares — an estimated $1.41M sold.

Antipodean Advisors first reported a position in PGEN in Q3 2016 and held it in 2 quarters. The position peaked at $1.41M in Q4 2016. 154 funds tracked by Wall St. Rank hold PGEN as of Q1 2017.

Antipodean Advisors reported no remaining Precigen position as of Q1 2017 after selling out during the quarter.
Antipodean Advisors sold 58,522 Precigen shares in Q1 2017, an estimated $1.41M.
Antipodean Advisors first reported a position in Precigen in Q3 2016 and held it in 2 quarters.
Antipodean Advisors's Precigen position peaked at $1.41M in Q4 2016.
154 funds tracked by Wall St. Rank held Precigen as of Q1 2017.

Based on Antipodean Advisors's 13F filing for Q1 2017, filed 15 May 2017.